A
Alcista
Alcista · 25%JANX
$60.28
Precio del escenario
$17.130
-0.050 (-0.29%)Al cierre
Loading chart…
- Máximo
- 17.490
- Apertura
- 17.130
- Precio medio ponderado por volumen
- 17.15
- Volumen
- 614.66K
- Capitalización
- 2.09B
- Mínimo
- 16.840
- Importe
- 10.54M
- EV/EBITDA, TTM
- -47.75
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Análisis de IA of Janux Therapeutics Inc (JANX)
ComprarJanux Therapeutics Inc is a good buy right now due to its recent price increase of 8.62% over the last five days and a strong RSI of 71.626, indicating bullish momentum. However, the company reported a Q2 EPS of -$0.35, missing expectations, which poses a risk to investor confidence.
Métricas de valoración
El PER previsto actual de Janux Therapeutics Inc (JANX) es 0.00, frente a su media de 5 años de -13.95.
Escenarios de precio de Alphio AI para JANX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con JANX en cartera
Cronología de eventos
Noticias
9.508-06seekingalphaJanux Therapeutics Q2 Earnings Miss Expectations
8.505-28Yahoo FinanceVERAXA Biotech Secures $27.5 Million Financing Agreement
6.505-23Yahoo FinanceProsight Management Increases Stake in Nektar Therapeutics
- 9.505-07seekingalpha
Janux Therapeutics Q1 Earnings Beat Expectations Despite Revenue Miss
8.504-27stocktwitsJanux Discontinues JANX008 Development to Focus on Other Pipeline Programs
Preguntas frecuentes sobre JANX, respondidas por Alphio AI
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Janux Therapeutics Inc is a good buy right now due to its recent price increase of 8.62% over the last five days and a strong RSI of 71.626, indicating bullish momentum. However, the company reported a Q2 EPS of -$0.35, missing expectations, which poses a risk to investor confidence.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.